You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 111 - 120 of 207714 results
  1. Digital University Platform Enhancements

    SBC: OMNI FED LLC            Topic: AF20RDCSO1

    In partnership with the Air Force PEO BES Software Factory, Omni Federal (Omni) has played an integral role in developing DU and launching the platform to the Air Force, democratizing digital learning and skills across the Air Force and Space Force. The M

    SBIR Phase II 2023 Department of DefenseAir Force
  2. High-efficiency Purcell-enhanced mid-infrared light emitting diodes and their arrays

    SBC: TRANSWAVE PHOTONICS, LLC            Topic: N211021

    TransWave Photonics proposes to develop 1024 x 1024 light emitting diode (LED) arrays capable to produce >15% wall-plug efficiency based on successful demonstration of single Purcell LED devices developed in Phase I. We will optimize the LED band structure, pixel geometry, and fabrication steps of Purcell LEDs and implement them to achieve the target specifications. Then, 1024x1024 addressable Pur ...

    SBIR Phase II 2023 Department of DefenseNavy
  3. ErythroMer: Nanoscale BioSynthetic Red Cell Substitute

    SBC: KaloCyte Inc            Topic: NHLBI

    Research Summary/Abstract ErythroMer (EM) is a novel biosynthetic blood substitute developed to address the critically unmet need for emergency transfusion in situations where the use of banked red blood cells (RBCs) are either not available or undesirable. EM is a self-assembled lipid-oligomeric hybrid nanoparticle with a high per particle payload of hemoglobin (Hb) and the allosteric modifier, R ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Concurrent Aerobic Exercise and Cognitive Training to Prevent Alzheimer's in at-risk Older Adults

    SBC: MOAI TECHNOLOGIES, LLC            Topic: NIA

    Project Summary/Abstract Alzheimer’s disease (AD) affects more than six million Americans currently and is projected to affect 14 million at a cost of $1.2 trillion in 2050. Despite its tremendous impacts and the limited influence of pharmacological therapies, attention has been brought to non-pharmacological interventions as promising therapeutic strategies for the prevention of cognitive decli ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Optimization of orally bioavailable inhibitors for the treatment of COVID-19 and other human coronavirus infections

    SBC: VENATORX PHARMACEUTICALS INC            Topic: NIAID

    PROJECT SUMMARY The emergence of SARS-CoV-2 in 2019 has resulted in an ongoing epidemic of acute respiratory illness that has stressed the world’s health care systems and led to rt6 million deaths. The lack of therapeutic options for treating coronavirus infections continues to expose the population to grave risk from emerging variants as well as future zoonotic coronavirus infections. Accelerat ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Development of a Group B Streptococcus bioconjugate vaccine

    SBC: VaxNewMO            Topic: NIAID

    PROJECT SUMMARY Streptococcus agalactiae, commonly referred to as Group B Streptococcus (GBS), is a leading cause of neonatal meningitis and sepsis worldwide. GBS neonatal disease manifests as early onset invasive disease, defined as disease between birth and 6 days of life, or late onset invasive disease, defined as disease occurring between 7 and 89 days. In some instances, early onset disease i ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Minimally invasive access and aspiration of circulating lymphocytes from the thoracic duct

    SBC: LXS, LLC            Topic: 300

    Building on a half-century of innovation in transvascular access and ultrasound image guidance, LXS has developed a novel catheter device and venous access procedure to cannulate and aspirate the thoracic duct under ultrasound guidance. The company has successfully completed Phase I and II of the NIH’s SBIR program and is applying for a Commercialization Readiness Pilot (CRP) award to complete d ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Advancing an accessible, high-throughput and multiplex islet autoantibody test with self-collected capillary dried blood spots for regulatory clearance

    SBC: Enable Biosciences Inc.            Topic: NIDDK

    Project Summary Type 1 diabetes, a chronic autoimmune disorder that affects millions of Americans is characterized by the progressive destruction of the insulin-producing islet cells of the pancreas, resulting in life-long dependency on insulin therapy. Many people with type 1 diabetes are diagnosed with life-threatening diabetic ketoacidosis and develop a panoply of perilous complications affecti ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Design of a bioactive mimetic of soluble klotho for the treatment of chronic kidney disease

    SBC: Alpha Young LLC            Topic: 400

    PROJECT SUMMARY Over 37 million individuals in the U.S. have chronic kidney disease (CKD) and are at high risk to die from cardiovascular complications. While great strides have been made to improve CKD care and dialysis access, minimal advances have been made in drug development to stall or reverse kidney damage and associated pathologies. Currently, therapeutic options to prevent cardiovascular ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  10. GMP manufacturing and IND Filing of IN-002, a potent inhaled muco-trapping antibody therapy for Respiratory Syncytial Virus

    SBC: Inhalon Biopharma Inc            Topic: NIAID

    Title: GMP manufacturing and IND Filing of IN-002, a potent inhaled “muco-trapping” antibody therapy for Respiratory Syncytial Virus Project Summary (30 line limit) Respiratory Syncytial Virus (RSV) is the leading cause of viral hospitalization and death in infants and young children and is also a major cause of respiratory illness in immune compromised adults and the elderly. Unfortunately, t ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government